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Abstract
Introduction: Neurologic consequences of manganese toxicity have been recognized since 1837. A new form of
presumed manganese poisoning has been reported in drug-addicted persons from Eastern Europe and the Baltic
states who have intravenously injected self-prepared methcathinone hydrochloride (ephedrone), which is
synthesized from pseudoephedrine hydrochloride using potassium permanganate as a potent oxidant. This clinical
syndrome is under-recognized in Western Europe and there are no reported cases in the literature from Ireland.
Case presentation: We report a 30-year-old Eastern European man who presented with a two-year history of gait
disturbance. A neurological assessment revealed features of parkinsonism which included hypophonia, hypomimia,
mild bradykinesia and rigidity with no resting tremor. He held his arms slightly abducted from his sides when
walking, with a reduction in arm swing. Magnetic resonance imaging of his brain showed a high signal on T1 in
the globus pallidus and serum manganese levels were raised. He had no response to levodopa.
Conclusion: Manganism secondary to ephedrone abuse causing parkinsonism has emerged in Western Europe in
recent years due to mass immigration and often remains unrecognized. This paper highlights the various features
of this rare cause of parkinsonism and aids in its recognition and subsequent diagnosis. Neurologists in Western
Europe will increasingly encounter such patients.
Introduction
Neurologic consequences of manganese toxicity have
been recognized since 1837 [1]. A new form of pre-
sumed manganese poisoning has been reported in drug-
addicted persons from Russia, Ukraine and Estonia who
have intravenously injected self-prepared methcathinone
hydrochloride, which is synthesized from pseudoephe-
drine hydrochloride using potassium permanganate as a
potent oxidant [2,3]. Methcathinone is a stimulant with
euphoric effects, known in Russia as ephedrone and by
the street names cat, mul’ka,a n djeff. We report a case
of manganese toxicity in an Irish hospital where this
entity is virtually unknown.
Case presentation
We report the case of a 30-year-old Eastern European
man who presented with a two-year history of gait dis-
turbance. Initial neurological assessment revealed hypo-
phonia, hypomimia, mild bradykinesia and rigidity with
no resting tremor. His eye movements were normal. A
cognitive and neuropsychological evaluation was unre-
markable. His gait showed a slight forward tilt of the
trunk from his hips on standing and he held his arms
slightly abducted from his sides when walking, with
reduction of the arm swing. He tended to walk on the
balls of his feet when going forward, seemingly falling
forward into the next stride. Moreover, on sitting down
from a standing position he deliberately placed himself
i nf r o n to ft h es e a ta n dg e n t l yf l e x e dh i sk n e e su n t i lh e
fell backward. He could not walk backward and had fre-
quent falls. His birth and family history were
unremarkable.
Initial investigations included the following laboratory
tests: erythrocyte sedimentation rate, autoimmune
screen, syphilis serology, vitamin B-12 and folate levels,
paraneoplastic screen, copper screen, and serology for
hepatitis B and human immunodeficiency virus. All
results were normal. Analysis of his cerebrospinal fluid
was normal. A chest X-ray and computed tomography
brain scan were also unremarkable. However, viral poly-
merase chain reaction for hepatitis C virus was positive.
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any medium, provided the original work is properly cited.increased signal in the globus pallidus on T1 sequences;
the signal was normal on T2 and fluid-attenuated inver-
sion recovery sequences (Figure 1). DaTSCAN (ioflu-
pane, 123-I-FP-CIT) imaging was performed in view of
his extrapyramidal features and showed normal striatal
morphology. He was treated with levodopa and the dose
was escalated to nearly 1000 mg/day without any clinical
response.
Our patient was discharged from hospital with a pro-
visional diagnosis of a possible somatoform disorder as
his symptoms could not be explained on an organic
basis at the time. He was followed up regularly over the
next two years in our neurology outpatient clinic. Serial
neurological examinations performed in our clinic over
this period remained unchanged. Therefore, a repeat
MRI of his brain was performed two years later and
showed the high signal on T1 in the globus pallidus had
completely resolved in comparison to the previous MRI
(Figure 2).
Although our patient denied current illicit drug use,
he admitted that he had been using a mixture of heroin,
pseudoephedrine (Sudafed), vinegar and potassium per-
manganate intravenously for two years before presenta-
tion. This cocktail was prepared in the home
environment and the formula was obtained from the
internet. This led us to suspect manganism as the cause
for his extrapyramidal features. Serum manganese levels
performed two years later were subsequently raised at
573 nmol/L (reference range: 73-218 nmol/L).
Discussion
The first case of parkinsonism caused by potassium per-
manganate was reported by Holzgraefe et al. in 1986
[4]. In our patient, parkinsonian symptoms had first
occurred nine months after poisoning. Manganese is an
essential trace metal required for a variety of enzymatic
and cellular processes within the human body [5].
Under normal dietary consumption, systemic
Figure 1 Brain MRI, T-1 sagittal view showing high signal in globus pallidus.
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of transport across enterocytes lining the intestinal wall
and by its efficient removal within the liver [6]. The
exact mechanism of action of manganese neurotoxicity
is unknown. In overexposure to manganese, a high con-
centration of Mn
3+ causes increased auto-oxidation of
dopamine in brain regions such as the nuclei of the
basal ganglia and leads to redundant generation of free
radicals [7].
The pathophysiology of manganese intoxication and
Parkinson’s disease are both associated with neurological
changes in the basal ganglia; the latter correlates with
loss of dopaminergic neurons within the nigrostriatal
pathway, whereas the former is associated with the pre-
ferential degeneration of gamma-aminobutyric acidergic
neurons within the globus pallidus.
The strongest evidence indicating the sparing of neu-
rons within the nigrostriatal pathway in manganism
comes from studies demonstrating that fluorodopa
scans are normal in individuals with high brain manga-
nese levels [8]. Ephedrone abuse is unknown in Ireland
and manganism due to ephedrone abuse is often not
suspected, primarily because it is uncommon and clini-
cal features are often mistaken for a somatoform disor-
der. There were several features that led us to suspect
manganism in our patient: lack of response to levodopa,
hypophonia, absent resting tremor, abnormal ‘cock-like’
gait, MRI brain scan with a high signal in the globus
pallidus on T1 sequences and history of ephedrone
abuse. There was no clinical improvement after cessa-
tion of ephedrone abuse.
The most important step in the management of man-
ganese toxicity is to prevent it. If removed from the
exposure within few weeks or months, the behavioral
and neurologic signs often resolve or improve, and can
stabilize within two years. In some cases, spontaneous,
Figure 2 Brain MRI, T-1 sagittal view shows the high signal has completely resolved two years later.
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years after initial exposure [9]. However, if the exposure
continues, the syndrome becomes irreversible.
Conclusion
Manganism secondary to ephedrone abuse causing par-
kinsonism has emerged in Western Europe in recent
years due to mass immigration. It should be suspected
in cases of atypical parkinsonism and the diagnosis can
be confirmed by measuring serum manganese levels in
the correct clinical context.
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